Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document 62009CN0066

    Case C-66/09: Reference for a preliminary ruling from the Lietuvos Aukščiausiasis Teismas (Republic of Lithuania) lodged on 16 February 2009 — Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras

    OJ C 90, 18.4.2009, p. 17–17 (BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    18.4.2009   

    EN

    Official Journal of the European Union

    C 90/17

    Reference for a preliminary ruling from the Lietuvos Aukščiausiasis Teismas (Republic of Lithuania) lodged on 16 February 2009 — Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras

    (Case C-66/09)

    2009/C 90/27

    Language of the case: Lithuanian

    Referring court

    Lietuvos Aukščiausiasis Teismas

    Parties to the main proceedings

    Claimant: Kirin Amgen, Inc.

    Defendant: Lietuvos Respublikos valstybinis patentų biuras

    Questions referred

    1.

    Is the date, referred to in Article 19(2) of Regulation No 1768/92, (1) upon which that regulation enters into force to be understood for Lithuania as the date of its accession to the European Union?

    2.

    Should the answer to the first question be in the affirmative, what is the relationship between Article 19 and Article 7 of Regulation No 1768/92 when calculating the six-month period and which of those articles is it necessary to apply in a case?

    3.

    Did an authorisation to place a product on the market in the European Community enter into force unconditionally in the Republic of Lithuania from the date of its accession to the European Union?

    4.

    Should the answer to the third question be in the affirmative, can the entry into force of the authorisation to place the product on the market be equated to its grant for the purposes of Article 3(b) of Regulation No 1768/92?

    (1)  Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products (OJ 1992 L 182, p. 1).

    Top